GlassScriptPhysician profile
Kersten E Woodlee
NPI 1154560555
$10,065.43
in general payments reported to CMS, 2019-2025
21 companies · $2,580 in 2025
The $2,580 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,483 · 2022: $2,051 · 2023: $2,031 · 2024: $1,920 · 2025: $2,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,514 · Education: $17.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,513.79 |
| Education | $17.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,597.46 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,471.23 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $1,438.09 | 2021-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $1,207.34 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $1,108.42 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $947.06 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $627.47 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $346.90 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $265.73 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $254.81 | 2021-2022 | |
| Lundbeck LLC | $246.33 | 2021-2025 | Rexulti |
| Indivior INC. | $199.26 | 2021-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $110.90 | 2021-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $61.90 | 2021-2022 | |
| Axsome Therapeutics, INC. | $56.17 | 2023-2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $44.90 | 2024 | Xelstrym, Secuado |
| Bausch Health US, LLC | $22.59 | 2022 | |
| Biogen, INC. | $19.25 | 2023 | |
| Tris Pharma INC | $13.84 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $13.82 | 2022 | |
| Harmony Biosciences LLC | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kersten Woodlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.